Literature DB >> 8576262

Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils.

C Knall1, S Young, J A Nick, A M Buhl, G S Worthen, G L Johnson.   

Abstract

Interleukin-8 (IL-8), the prototypic member of the CXC subfamily of chemokines, induces in neutrophils chemotaxis, the respiratory burst, granule release, and increased cell adhesion. The IL-8 receptor is a seven-transmembrane spanning receptor coupled to specific heterotrimeric G proteins including Gi and G16. IL-8 stimulation of its receptor on neutrophils activates Ras GTP loading and the mitogen-activated protein kinase (MAPK) pathway including Raf-1 and B-Raf. The properties of IL-8 stimulation of the MAPK pathway differ from those observed for chemoattractants such as C5a. Even though Ras GTP loading is similar for IL-8 and C5a, the maximal activation of Raf-1 and B-Raf is approximately 2-fold and 3-7-fold, respectively, less for IL-8 than that observed for C5a. Raf-1 activation is rapid but transient, returning to near basal levels by 10 min. B-Raf activation is slower in onset and does not return to basal levels for nearly 30 min. IL-8 activation of MAPK follows a time course suggesting an involvement of both Raf-1 and B-Raf. Surprisingly, wortmannin, at low concentrations, inhibits Raf-1, B-Raf, and MAPK activation in response to IL-8 and C5a demonstrating a role for phosphatidylinositol 3-kinase in the activation of Raf kinases in G protein-coupled receptor systems in human neutrophils. Furthermore, wortmannin inhibits IL-8 stimulated granule release and neutrophil adherence. These findings demonstrate the control of Raf kinases, the MAPK pathway and specific neutrophil functions by phosphatidylinositol 3-kinase enzymes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8576262     DOI: 10.1074/jbc.271.5.2832

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

Review 1.  Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases.

Authors:  Adam P Curnock; Marisa K Logan; Stephen G Ward
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 2.  CXC chemokine receptors in the central nervous system: Role in cerebellar neuromodulation and development.

Authors:  Davide Ragozzino
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

3.  Evaluation of signal transduction pathways in chemoattractant-induced human monocyte chemotaxis.

Authors:  J S Fine; H D Byrnes; P J Zavodny; R W Hipkin
Journal:  Inflammation       Date:  2001-04       Impact factor: 4.092

Review 4.  A primer on cytokines: sources, receptors, effects, and inducers.

Authors:  J H Curfs; J F Meis; J A Hoogkamp-Korstanje
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

5.  Inhibition of kinases impairs neutrophil activation and killing of Staphylococcus aureus.

Authors:  B Schnyder; P C Meunier; B D Car
Journal:  Biochem J       Date:  1998-04-15       Impact factor: 3.857

Review 6.  Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?

Authors:  Mike Veenstra; Richard M Ransohoff
Journal:  J Neuroimmunol       Date:  2012-03-22       Impact factor: 3.478

Review 7.  Moving towards a paradigm: common mechanisms of chemotactic signaling in Dictyostelium and mammalian leukocytes.

Authors:  Yulia Artemenko; Thomas J Lampert; Peter N Devreotes
Journal:  Cell Mol Life Sci       Date:  2014-05-21       Impact factor: 9.261

8.  Nerve growth factor activation of the extracellular signal-regulated kinase pathway is modulated by Ca(2+) and calmodulin.

Authors:  J Egea; C Espinet; R M Soler; S Peiró; N Rocamora; J X Comella
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

Review 9.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

10.  Intracellular signaling by the chemokine receptor US28 during human cytomegalovirus infection.

Authors:  M A Billstrom; G L Johnson; N J Avdi; G S Worthen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.